According to a new report published by Allied Market Research, titled,
"Cholera
Vaccine Market by Product and End User: Global Opportunity Analysis and
Industry Forecast, 2018-2025," the global cholera vaccine
market generated USD 65 million in 2017, and is projected to reach USD 207
million by 2025, growing at a CAGR of 15.6% from 2018 to 2025. The Dukoral
segment accounted around half of the total market share in 2017.
Cholera is an acute, profusely watery diarrhea caused by Vibrio cholera
and spreads through contamination of water and food. In addition, it is closely
associated with poor sanitation and lack of clean drinking water. The number of
global cholera disease cases accounts for around 35 million every year.
Currently, the frequency of cholera epidemics has increased mainly in low- and
middle-income countries. Cholera control is the main priority in
cholera-endemic areas, which in turn increase the demand for the cholera
vaccines.
The cholera vaccine market is
expected to exhibit significant growth during the forecast period due to lack
of proper sanitation & consumption of contaminated food and growth in
awareness about cholera preventive care. In addition, development of novel
approaches for new cholera vaccine further drive the market growth. However,
risk of adverse effects and the time taken for the regulatory approval is
projected to impede the market growth. On the contrary, high growth
opportunities in untapped markets are expected to offer significant profitable
opportunities for the market players in the near future.
Based on end user, the market is categorized into hospitals & clinics,
research & academic laboratories, and others. The hospitals & clinics
segment presently dominates the market, and is expected to remain dominant
during the forecast period. This is attributed to the fact that hospitals and
clinics are authorized to organize campaigns for cholera vaccination, as the
number of cases for cholera diseases is rapidly growing in LMICs.
Asia-Pacific was the leading revenue contributor to the global cholera
vaccine market in 2017, and is expected to remain dominant throughout the
forecast period due to increase in the prevalence of cholera disease and rise
in importance of immunization. However, North America is expected to grow at
the highest CAGR during the study period. This is attributed to the launch of
the first and only oral cholera vaccine, Vaxchora, in the USA. Furthermore, the
number of travelers to the cholera-affected countries is increasing, which in
turn increases the demand for immunization.
The report provides a comprehensive analysis of the key players operating
in the global cholera vaccine market
namely Valneva SE, Emergent BioSolutions, Inc. (PaxVax, Inc.), Astellas Pharma,
Inc., Sanofi (Shantha Biotechnics Private Limited), Eubiologics Co., Ltd., and
Johnson & Johnson (Crucell), Celldex Therapeutics, Inc. The other players
in the in the cholera vaccine market industry include Merck & Co., Inc.,
GlaxoSmithKline plc., and others.
Based on product, the Vaxchora segment is expected to experience rapid
growth in the market, and is projected to grow at a CAGR of 17.4% from 2018 to
2025. Depending on end user, the pharmaceutical & biotechnology
companies segment is expected to exhibit the highest CAGR during the forecast
period. U.S. generated the highest revenue in the global cholera vaccine
market industry in 2017, accounting less than one-tenth of the global market in
2017. North America is estimated to grow at a CAGR of 17.1% during the
forecast period.
For more information on the research report, refer to below
link:-
Contact Us:-
Ken Research
Ankur Gupta,
Head Marketing & Communications
+91-9015378249
